Crosstalk between monocytes and renal mesangial cells via interaction of metalloproteinases and fractalkine in diabetic nephropathy

Wang,Yanping; Wei,Qiong; Liu,Qiang; Li,Zheng; Zhou,Li; Zou,Fang; Yuan,Yang; Sun,Zilin

doi:10.3892/mmr.2013.1703

Crosstalk between monocytes and renal mesangial cells via interaction of metalloproteinases and fractalkine in diabetic nephropathy

Authors:
- Yanping Wang
- Qiong Wei
- Qiang Liu
- Zheng Li
- Li Zhou
- Fang Zou
- Yang Yuan
- Zilin Sun
View Affiliations

Affiliations: Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Medical School, Southeast University, Nanjing, Jiangsu 210009, P.R. China
Published online on: September 25, 2013 https://doi.org/10.3892/mmr.2013.1703
Pages: 1817-1823

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An increasing number of studies suggest that the activation of innate immunity with the development of a chronic low‑grade inflammatory response is a factor in the pathogenesis of diabetic nephropathy (DN). Advanced glycation end products (AGEs), chemokines and matrix metalloproteinases (MMPs) are known to be important in inflammatory reactions in DN. In the present study, the inter-regulation of MMP2 and fractalkine was observed between monocytes (U937) and human renal mesangial cells (HRMCs) and its potential pathophysiological role in DN. The expression of fractalkine and MMP2 was analyzed by RT-PCR, western blot analysis and enzyme‑linked immunosorbent assay. The chemotaxis and adhesiveness of HRMCs to U937 cells was detected with a transwell system, co‑culture and fluorescent staining, respectively. The results showed a decreased expression of MMP2 and an increased expression of fractalkine by AGEs in HRMCs. Fractalkine downregulated the mRNA expression and activity of MMP2, and the reduced MMP2 activity was reversed with an anti‑fractalkine antibody. Conversely, MMP2 upregulated fractalkine mRNA and protein expression in HRMCs, which led to an increase in chemotaxis and a decrease in monocytic adhesion to HRMCs. In conclusion, these observations suggest a crosstalk between monocytes and HRMCs via the interaction of MMP2 and fractalkine, which may represent a therapeutic target to impede the inflammatory process associated with DN.

View Figures

View References

1	Kaul K, Hodgkinson A, Tarr JM, Kohner EM and Chibber R: Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Curr Diabetes Rev. 6:294–303. 2010. View Article : Google Scholar : PubMed/NCBI
2	Busch M, Franke S, Rüster C and Wolf G: Advanced glycation end-products and the kidney. Eur J Clin Invest. 40:742–755. 2010. View Article : Google Scholar : PubMed/NCBI
3	Yamagishi S: Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol. 46:217–224. 2011. View Article : Google Scholar : PubMed/NCBI
4	Navarro-González JF and Mora-Fernández C: Inflammatory pathways. Contrib Nephrol. 170:113–123. 2011.
5	Yamagishi S and Imaizumi T: Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 11:2279–2299. 2005. View Article : Google Scholar
6	van Dijk C and Berl T: Pathogenesis of diabetic nephropathy. Rev Endocr Metab Disord. 5:237–248. 2004.
7	Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K and Yoshinaga K: The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis. 21:480–485. 1993. View Article : Google Scholar : PubMed/NCBI
8	Nguyen D, Ping F, Mu W, Hill P, Atkins RC and Chadban SJ: Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton). 11:226–231. 2006. View Article : Google Scholar : PubMed/NCBI
9	Yonemoto S, Machiguchi T, Nomura K, Minakata T, Nanno M and Yoshida H: Correlations of tissue macrophages and cytoskeletal protein expression with renal fibrosis in patients with diabetes mellitus. Clin Exp Nephrol. 10:186–192. 2006. View Article : Google Scholar : PubMed/NCBI
10	Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC and Tesch GH: Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 65:116–128. 2004. View Article : Google Scholar : PubMed/NCBI
11	Braunersreuther V, Mach F and Steffens S: The specific role of chemokines in atherosclerosis. Thromb Haemost. 97:714–721. 2007.PubMed/NCBI
12	Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A and Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature. 385:640–644. 1997. View Article : Google Scholar : PubMed/NCBI
13	Wong BW, Wong D and McManus BM: Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol. 11:332–338. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kikuchi Y, Ikee R, Hemmi N, Hyodo N, Saigusa T, Namikoshi T, Yamada M, Suzuki S and Miura S: Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. Nephron Exp Nephrol. 97:e17–e25. 2004. View Article : Google Scholar : PubMed/NCBI
15	Lesnik P, Haskell CA and Charo IF: Decreased atherosclerosis in CX3CR1^−/− mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 111:333–340. 2003.PubMed/NCBI
16	Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 92:827–839. 2003. View Article : Google Scholar : PubMed/NCBI
17	Corbel M, Belleguic C, Boichot E and Lagente V: Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol. 18:51–61. 2002. View Article : Google Scholar : PubMed/NCBI
18	John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 7:14–23. 2001. View Article : Google Scholar : PubMed/NCBI
19	Brosius FC III: New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord. 9:245–254. 2008. View Article : Google Scholar : PubMed/NCBI
20	Alsaad KO and Herzenberg AM: Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol. 60:18–26. 2007. View Article : Google Scholar : PubMed/NCBI
21	Mason RM and Wahab NA: Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol. 14:1358–1373. 2003. View Article : Google Scholar : PubMed/NCBI
22	Nagase H and Woessner JF Jr: Matrix metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar
23	Sun Z, Liu N and Liu B: The preparation and application of antiserum against advanced glycated end products. Chin J Lab Med. 5:293–295. 1999.(In Chinese).
24	Zilin S, Naifeng L, Bicheng L and Jiping W: The determination of AGE-peptides by flow injection assay, a practical marker of diabetic nephropathy. Clin Chim Acta. 313:69–75. 2001. View Article : Google Scholar : PubMed/NCBI
25	Kenig S, Alonso MB, Mueller MM and Lah TT: Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. Cancer Lett. 289:53–61. 2010. View Article : Google Scholar : PubMed/NCBI
26	Tang CH, Tan TW, Fu WM and Yang RS: Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis. 29:35–43. 2008. View Article : Google Scholar : PubMed/NCBI
27	Vitale S, Schmid-Alliana A, Breuil V, Pomeranz M, Millet MA, Rossi B and Schmid-Antomarchi H: Soluble fractalkine prevents monocyte chemoattractant protein-1-induced monocyte migration via inhibition of stress-activated protein kinase 2/p38 and matrix metalloproteinase activities. J Immunol. 172:585–592. 2004. View Article : Google Scholar
28	Klier CM, Nelson EL, Cohen CD, Horuk R, Schlöndorff D and Nelson PJ: Chemokine-induced secretion of gelatinase B in primary human monocytes. Biol Chem. 382:1405–1410. 2001. View Article : Google Scholar : PubMed/NCBI
29	Cross AK and Woodroofe MN: Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia. 28:183–189. 1999. View Article : Google Scholar : PubMed/NCBI
30	Madri JA and Graesser D: Cell migration in the immune system: the evolving inter-related roles of adhesion molecules and proteinases. Dev Immunol. 7:103–116. 2000. View Article : Google Scholar : PubMed/NCBI
31	Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ and Raines EW: Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem. 276:37993–38001. 2001.PubMed/NCBI
32	Tsou CL, Haskell CA and Charo IF: Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem. 276:44622–44626. 2001. View Article : Google Scholar : PubMed/NCBI
33	Théret N, Musso O, L'Helgoualc'h A and Clément B: Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interactions with hepatocytes. Am J Pathol. 150:51–58. 1997.PubMed/NCBI
34	Théret N, Lehti K, Musso O and Clément B: MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology. 30:462–468. 1999.PubMed/NCBI
35	Bourd-Boittin K, Basset L, Bonnier D, L'Helgoualc'h A, Samson M and Théret N: CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. J Cell Mol Med. 13:1526–1535. 2009. View Article : Google Scholar : PubMed/NCBI
36	Dean RA and Overall CM: Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics. 6:611–623. 2007. View Article : Google Scholar : PubMed/NCBI
37	Inoue A, Hasegawa H, Kohno M, Ito MR, Terada M, Imai T, Yoshie O, Nose M and Fujita S: Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum. 52:1522–1533. 2005. View Article : Google Scholar : PubMed/NCBI